IBS Treatment Market Information: By Types, By Drugs Type, By End Users - Americas Forecast Till 2023

Published - Jan 2019 | Category - Healthcare | No. of Pages - 100 | Published By - Market Research Future


Americas IBS treatment market is projected to grow at a CAGR of 9.3% during the forecast period 2017-2023.


IBS Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) - Americas Forecast Till 2023

Market Analysis

Irritable bowel syndrome (IBS) is one of the major disorders affecting the digestive system of humans. Diarrhea, bloating, stomach cramps, and constipation, are some of the symptoms of the disorder. In spite of the fact that the reason for IBS is obscure, however, few factors that cause IBS are extreme disease, inflammation of the digestion tracts, contraction of muscles in the intestine, changes in gut bacteria, and nerve disorders. The rising pervasiveness of gastrointestinal infections and confusion, the geriatric populace, undesirable eating regimen, uneasiness, depression, and changing way of life in the Americas are the key drivers of the Americas IBS market. The Americas IBS treatment market is projected to grow at a CAGR of 9.3% during the forecast period 2017-2023.

Moreover, expanding consumer awareness about the IBS syndrome has increased the footfall of patient in the hospitals and other healthcare centers. Moreover, expanding expenditure in the medicinal services area is fueling the development of the IBS treatment market. However, strict FDA controls and inadmissible adequacy of the treatment may harm the development of the Americas IBS treatment market amid the forecast period (2017-2023).


 

Quick Buy

Latest Publications